ABSTRACT Replication-competent vesicular stomatitis virus (VSV)-based recombinant viruses are useful tools for studying emerging and highly pathogenic enveloped viruses in level 2 biosafety facilities. Here, we used a replication-competent recombinant VSVs (rVSVs) encoding the spike (S) protein of SARS-CoV-2 in place of the original G glycoprotein (rVSV-eGFP-SARS-CoV-2) to develop a high-throughput entry assay for SARS-CoV-2. The S protein was incorporated into the recovered rVSV-eGFP-SARS-CoV-2 particles, which could be neutralized by sera from convalescent COVID-19 patients. The recombinant SARS-CoV-2 also displayed entry characteristics similar to the wild type virus, such as cell tropism and pH-dependence. The neutralizing titers of antibodies and sera measured by rVSV-eGFP-SARS-CoV-2 were highly correlated with those measured by wild-type viruses or pseudoviruses. Therefore, this is a safe and convenient screening tool for SARS-CoV-2, and it may promote the development of COVID-19 vaccines and therapeutics.
【저자키워드】 SARS-CoV-2, VSV, Neutralization assay, Entry, replication-competent, 【초록키워드】 COVID-19 vaccine, S protein, antibody, virus, biosafety, Protein, Characteristics, sera, cell tropism, wild type, vesicular stomatitis virus, Neutralizing titer, convalescent COVID-19 patients, Safe, pseudoviruses, Particles, wild-type, highly pathogenic, G glycoprotein, neutralized, develop, correlated, promote, 【제목키워드】 virus, SARS-CoV-2 entry, stomatitis,